Aileron Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2005)

Organization Overview

First Clinical Trial
2013
NCT01775358
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Aileron Therapeutics | Aileron Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Preleukemia (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 7